Patents Assigned to Vaxiion Therapeutics, Inc.
  • Patent number: 9017986
    Abstract: Minicells are used to deliver biologically active compounds including radioisotopes, polypeptides, nucleic acids, small molecules, drug molecules, and chemotherapeutic agents. In some cases, the minicell displays ligands or binding moieties that target the minicell to a desired host cell.
    Type: Grant
    Filed: August 1, 2013
    Date of Patent: April 28, 2015
    Assignee: Vaxiion Therapeutics, Inc.
    Inventors: Roger Sabbadini, Neil Berkley, Mark Surber, Robert Klepper
  • Publication number: 20130337545
    Abstract: Minicells are used to deliver biologically active compounds including radioisotopes, polypeptides, nucleic acids, small molecules, drug molecules, and chemotherapeutic agents. In some cases, the minicell displays ligands or binding moieties that target the minicell to a desired host cell.
    Type: Application
    Filed: August 1, 2013
    Publication date: December 19, 2013
    Applicant: Vaxiion Therapeutics, Inc.
    Inventors: ROGER SABBADINI, Neil Berkley, Mark Surber, Robert Klepper
  • Patent number: 8524484
    Abstract: The disclosed invention relates to immunogenic minicells cells (anucleated) and their use to induce an immune response from a subject.
    Type: Grant
    Filed: March 5, 2012
    Date of Patent: September 3, 2013
    Assignee: Vaxiion Therapeutics, Inc.
    Inventors: Roger A. Sabbadini, Neil Berkley, Mark W. Surber, Matthew J. Giacalone
  • Publication number: 20130210121
    Abstract: Embodiments of the present invention relates to the incorporation and use of a regulated genetic suicide mechanism for use in the improved purification of biologics, including adjunct use in various eubacterial minicell production and purification methodologies. Described herein are high-yield eubacterial minicell-producing strains with genetic modifications that comprise a regulated genetic suicide mechanism that irreparably destroys the parent cell chromosome such that live parental cells in a culture can be functionally eliminated at any time during the course of a minicell production and purification run. Embodiments of the present invention also describe methods useful in the elimination of live parental cells during the production of other cell-based biologics.
    Type: Application
    Filed: December 11, 2012
    Publication date: August 15, 2013
    Applicant: VAXIION THERAPEUTICS, INC.
    Inventor: Vaxiion Therapeutics, Inc.
  • Publication number: 20120252099
    Abstract: The disclosed invention relates to immunogenic minicells cells (anucleated) and their use to induce an immune response from a subject.
    Type: Application
    Filed: March 5, 2012
    Publication date: October 4, 2012
    Applicant: Vaxiion Therapeutics, Inc.
    Inventors: Roger A. Sabbadini, Neil Berkley, Mark W. Surber, Matthew J. Giacalone
  • Publication number: 20120207754
    Abstract: The present application relates to the use of bacterial minicells as targeted delivery agents in vivo and in vitro. Described herein are genetically engineered eubacterial minicells designed to preferentially target and deliver therapeutically relevant agents using a minicell surface coupling molecule capable of binding and displaying antibodies or other Fc-containing targeting moiety fusions and conjugates.
    Type: Application
    Filed: February 15, 2012
    Publication date: August 16, 2012
    Applicant: Vaxiion Therapeutics, Inc.
    Inventors: Matthew J. Giacalone, Michael J. Newman
  • Publication number: 20120142079
    Abstract: Minicells are used to deliver biologically active compounds including radioisotopes, polypeptides, nucleic acids, small molecules, drug molecules, and chemotherapeutic agents. In some cases, the minicell displays ligands or binding moieties that target the minicell to a desired host cell.
    Type: Application
    Filed: November 11, 2011
    Publication date: June 7, 2012
    Applicant: Vaxiion Therapeutics, Inc.
    Inventors: Roger A. Sabbadini, Neil Berkley, Mark W. Surber, Robert Klepper
  • Publication number: 20120135503
    Abstract: Minicells are used to deliver biologically active compounds including radioisotopes, polypeptides, nucleic acids, small molecules, drug molecules, and chemotherapeutic agents. In some cases, the minicell displays ligands or binding moieties that target the minicell to a desired host cell.
    Type: Application
    Filed: November 11, 2011
    Publication date: May 31, 2012
    Applicant: Vaxiion Therapeutics, Inc.
    Inventors: Roger A. Sabbadini, Neil Berkley, Mark W. Surber
  • Patent number: 8129166
    Abstract: The disclosed invention relates to immunogenic minicells cells (anucleated) and their use to induce an immune response from a subject.
    Type: Grant
    Filed: June 4, 2008
    Date of Patent: March 6, 2012
    Assignee: Vaxiion Therapeutics, Inc.
    Inventors: Roger A. Sabbadini, Neil Berkley, Mark Surber
  • Patent number: 8101396
    Abstract: Minicells are used to deliver biologically active compounds including radioisotopes, polypeptides, nucleic acids, small molecules, drug molecules, and chemotherapeutic agents. In some cases, the minicell displays ligands or binding moieties that target the minicell to a desired host cell.
    Type: Grant
    Filed: March 16, 2007
    Date of Patent: January 24, 2012
    Assignee: Vaxiion Therapeutics, Inc.
    Inventors: Roger A. Sabbadini, Neil Berkley, Mark W. Surber, Robert Klepper
  • Publication number: 20110281330
    Abstract: Minicells are used to deliver biologically active compounds including radioisotopes, polypeptides, nucleic acids, small molecules, drug molecules, and chemotherapeutic agents. In some cases, the minicell displays ligands or binding moieties that target the minicell to a desired host cell.
    Type: Application
    Filed: March 16, 2007
    Publication date: November 17, 2011
    Applicant: VAXIION THERAPEUTICS, INC.
    Inventors: Roger A. Sabbadini, Neil Berkley, Mark W. Surber
  • Patent number: 7871815
    Abstract: Disclosed herein is a rhamnose-inducible expression vector.
    Type: Grant
    Filed: October 11, 2006
    Date of Patent: January 18, 2011
    Assignee: Vaxiion Therapeutics, Inc.
    Inventors: Roger A. Sabbadini, Neil Berkley, Mark W. Surber
  • Publication number: 20100112670
    Abstract: Embodiments of the present invention relates to the incorporation and use of a regulated genetic suicide mechanism for use in the improved purification of biologics, including adjunct use in various eubacterial minicell production and purification methodologies. Described herein are high-yield eubacterial minicell-producing strains with genetic modifications that comprise a regulated genetic suicide mechanism that irreparably destroys the parent cell chromosome such that live parental cells in a culture can be functionally eliminated at any time during the course of a minicell production and purification run. Embodiments of the present invention also describe methods useful in the elimination of live parental cells during the production of other cell-based biologics.
    Type: Application
    Filed: June 23, 2009
    Publication date: May 6, 2010
    Applicant: Vaxiion Therapeutics, Inc.
    Inventors: Matthew J. Giacalone, Stanley Maloy, Shingo Tsuji
  • Publication number: 20090011490
    Abstract: The disclosed invention relates to immunogenic minicells cells (anucleated) and their use to induce an immune response from a subject.
    Type: Application
    Filed: June 4, 2008
    Publication date: January 8, 2009
    Applicant: Vaxiion Therapeutics, Inc.
    Inventors: Roger A. Sabbadini, Neil Berkley, Mark Surber
  • Publication number: 20090004744
    Abstract: The disclosed invention relates to immunogenic minicells cells (anucleated) and their use to induce an immune response from a subject.
    Type: Application
    Filed: April 30, 2008
    Publication date: January 1, 2009
    Applicant: Vaxiion Therapeutics, Inc.
    Inventors: Mark W. Surber, Roger Sabbadini, Neil Berkley
  • Patent number: 7396822
    Abstract: The disclosed invention relates to immunogenic minicells cells (anucleated) and their use to induce an immune response from a subject.
    Type: Grant
    Filed: April 26, 2004
    Date of Patent: July 8, 2008
    Assignee: Vaxiion Therapeutics, Inc.
    Inventors: Roger A. Sabbadini, Neil Berkley, Mark Surber
  • Patent number: 7183105
    Abstract: Th invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnositic and therapeutic uses, as well as research tools and agents for drug discovery.
    Type: Grant
    Filed: May 28, 2002
    Date of Patent: February 27, 2007
    Assignee: Vaxiion Therapeutics, Inc.
    Inventors: Roger A. Sabbadini, Neil Berkley, Mark W. Surber